Table 1. Characteristics of patients demonstrating clinical similarity between Recovered and Dependent groups prior to VAD implantation, in both Test and Validation cohorts.
Duration of congestive heart failure (CHF) was defined as the time in days from original presentation with heart failure until VAD placement. Days on VAD was defined as time to VAD explant (Recovered group) or Transplantation (Dependent group). All patients on pulsatile VAD support were on Thoratec (Pleasanton CA) extracorporeal devices. PCWP and cardiac index measured immediately prior to VAD implantation, while on inotropes.
| Clinical Characteristics At Baseline
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Test Cohort | Validation Cohort | NonFailing Controls | Test Vs Validation Cohorts | All VAD Vs NonFailing Controls | |||||
| Recovered | Dependent | p Value | Recovered | Dependent | p Value | p Value | p Value | ||
| Number of Patients | 7 | 7 | 7 | 7 | 7 | ||||
| Age (years) | 40±12 | 42±15 | NS | 27±8 | 33±9 | NS | 36±10 | NS | NS |
| Percent Ischemic | 0 | 0 | NS | 0 | 0 | NS | 0 | NS | NS |
| Inotropic Support | 100% | 100% | NS | 85% | 100% | NS | 0 | NS | <0.001 |
| Intraaortic Balloon Pump | 43% | 57% | NS | 43% | 14% | NS | 0 | NS | <0.001 |
| Other Mechanical Support (TandemHeart) | 0% | 0% | NS | 14% | 14% | NS | 0 | NS | <0.001 |
| Percent Male | 50% | 50% | NS | 71% | 71% | NS | 50% | <0.04 | NS |
| EF Prior to VAD (%) | 18±5 | 15±5 | NS | 18±5 | 17±5 | NS | 65±10 | NS | <0.001 |
| LVEDd Prior to VAD (cm) | 6.0±0.8 | 6.2±0.8 | NS | 7.0±1.0 | 7.0±1.0 | NS | Data not available | <0.02 | Data not available |
| PCWP Prior to VAD (mm Hg)* | 26±9 | 27±10 | NS | 27±5 | 27±11 | NS | Data not available | NS | Data not available |
| Cardiac Index Prior to VAD (L/min/m2)* | 1.9±0.89 | 2.0±0.73 | NS | 1.6±0.24 | 1.8±0.41 | NS | Data not available | NS | Data not available |
| Duration of CHF (days) | 62±49 | 75±58 | NS | 680±1117 | 771±802 | NS | NA | <0.001 | NA |
| Type of VAD (% Rotary) | 14% | 14% | NS | 71% | 42% | NS | NA | <0.01 | NA |
| Days on VAD | 53±31 | 61±29 | NS | 433±250 | 369±167 | NS | NA | <0.001 | NA |
| Clinical Characteristics At 6 Month Follow Up Post VAD Explantation
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Test Cohort | Validation Cohort | NonFailing Controls | Test Vs Validation Cohorts | |||||
| Recovered | Dependent | p Value | Recovered | Dependent | p Value | p Value | ||
| Number of Patients | 5 | 5 | 7 | 7 | NA | |||
| Betablocker use while on VAD | 67% | 83% | NS | 100% | 85% | NS | NA | NS |
| ACE Inhibitor use while on VAD | 83% | 83% | NS | 85% | 85% | NS | NA | NS |
| EF at 6 months post explantation (%) | 55±5 | N/A | - | 43±11 | N/A | NA | <0.04 | |
NS: not significant;
NA: Not applicable.